tert-butyl N-[(2S)-1-oxo-1-(5-thiophen-2-yl-1,3,4-oxadiazol-2-yl)pentan-2-yl]carbamate | 896740-95-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: tert-butyl N-[(2S)-1-oxo-1-(5-thiophen-2-yl-1,3,4-oxadiazol-2-yl)pentan-2-yl]carbamate
• CAS: 896740-95-7
• 化学式: C₁₆H₂₁N₃O₄S
• 分子量: 351.426
• InChiKey: HKXMUSYUJHMGHH-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  24
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  123
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  tert-butyl ((2S)-1-hydroxy-1-(5-(thiophen-2-yl)-1,3,4-oxadiazol-2-yl)pentan-2-yl)carbamate 在 戴斯-马丁氧化剂 作用下， 以 二氯甲烷 为溶剂， 生成 tert-butyl N-[(2S)-1-oxo-1-(5-thiophen-2-yl-1,3,4-oxadiazol-2-yl)pentan-2-yl]carbamate
  参考文献：
  名称：

  Keto-1,3,4-oxadiazoles as cathepsin K inhibitors

  摘要：

  We have prepared a series of cathepsin K inhibitors bearing the keto-1,3,4-oxadiazole warhead capable of forming a hemithioketal complex with the target enzyme. By modifying binding moieties at the P-1, P-2, and prime side positions of the inhibitors, we have achieved selectivity over cathepsins B, L, and S, and have achieved sub-nanomolar potency against cathepsin K. This series thus represents a promising chemotype that could be used in diseases implicated by imbalances in cathepsin K activity such as osteoporosis. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.03.001

文献信息

• Keto-1,3,4-oxadiazoles as cathepsin K inhibitors
  作者：James T. Palmer、Bernard L. Hirschbein、Harry Cheung、John McCarter、James W. Janc、Z. Walter Yu、Gregg Wesolowski

  DOI：10.1016/j.bmcl.2006.03.001

  日期：2006.6

  We have prepared a series of cathepsin K inhibitors bearing the keto-1,3,4-oxadiazole warhead capable of forming a hemithioketal complex with the target enzyme. By modifying binding moieties at the P-1, P-2, and prime side positions of the inhibitors, we have achieved selectivity over cathepsins B, L, and S, and have achieved sub-nanomolar potency against cathepsin K. This series thus represents a promising chemotype that could be used in diseases implicated by imbalances in cathepsin K activity such as osteoporosis. (c) 2006 Elsevier Ltd. All rights reserved.